Isodiol Worldwide Inc. – Delay In Submitting Audited Monetary Statements – Obtains Administration Stop Commerce Order from BCSC

[ad_1]

July 30, 2019 – Vancouver, BC –  Isodiol Worldwide Inc. (CSE: ISOL) (OTCQB:ISOLF)
(FSE: LB6B.F)(the “Firm” or “Isodiol”), right now declares a delay within the submitting of its audited
annual monetary statements, associated administration’s dialogue and evaluation and supporting
officer certificates for the monetary 12 months ended March 31, 2019 (the “Filings”). The Filings are
required to be made with the related securities regulatory authorities on or earlier than July 29,
2019.

The anticipated delay of its Filings is a results of delays in having access to accounting
data pursuant to inclinations of subsidiaries for which the Firm now not has
administration affect over.

The Firm notes that such delays have been resolved and the Firm is now within the last
levels of the audit and anticipates finishing its Filings earlier than August 16, 2019.

The Firm has obtained a administration stop commerce order from the related securities
regulators as contemplated by Nationwide Coverage 12-203 Administration Stop Commerce Orders of the
Canadian Securities Directors. The Firm will adjust to the necessities of the
various data tips set out within the Nationwide Coverage. The Firm is just not topic to
any insolvency proceedings.

The Firm additionally declares the departure of Kevin Swadish, Chief Income Officer and
Patrick Ogle as a Director and Chief Working Officer of the Firm.

Observe Our Company Updates On Fb at www.fb.com/IsodiolInternationalInc/,
on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol Worldwide Inc.

Isodiol Worldwide Inc. is concentrated on the dietary well being advantages which might be derived from hemp
and is a product growth, gross sales, advertising and marketing and distribution firm of hemp-based
Shopper Packaged Items (CPG) and options. Isodiol has commercialized a 99%+ pure,
naturally remoted CBD, together with micro-encapsulations, and nano-technology for high quality
consumable and topical skincare merchandise. The Firm obtained approval for its CBD as an
Lively Pharmaceutical Ingredient (API) to be used in Completed Pharmaceutical Merchandise (FPPs), as was
introduced on April 26, 2018. Isodiol’s progress technique consists of the event of over-thecounter
and pharmaceutical medication and continued worldwide enlargement into Latin America,
Asia, and Europe.

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
[email protected]
604-409-4409

MEDIA CONTACT:
Christopher Hussey
[email protected]

The CSE has not reviewed, permitted or disapproved the content material of this press launch.

Ahead-Wanting Data: This information launch comprises “forward-looking data” inside
the that means of relevant securities legal guidelines regarding statements concerning the Firm’s
enterprise, proposed association with collectors, merchandise and future the Firm’s enterprise, its
product choices and plans for gross sales and advertising and marketing. Though the Firm believes that the
expectations mirrored within the forward-looking data are affordable, there might be no
assurance that such expectations will show to be appropriate. Readers are cautioned to not place
undue reliance on forward-looking data. Such forward-looking statements are topic to
dangers and uncertainties that will trigger precise outcomes, efficiency and developments to vary
materially from these contemplated by these statements relying on, amongst different issues, the
dangers that the Firm’s merchandise and plan will fluctuate from these said on this information launch and
the Firm might not be capable to perform its enterprise plans as anticipated. Besides as required by
legislation, the Firm expressly disclaims any obligation and doesn’t intend, to replace any forwardlooking
statements or forward-looking data on this information launch. Though the Firm
believes that the expectations mirrored within the forward-looking data are affordable, there
might be no assurance that such expectations will show to be appropriate and makes no reference to
profitability based mostly on gross sales reported. The statements on this information launch are made as of the date
of this launch.

The CSE has not reviewed, permitted or disapproved the content material of this press launch.



[ad_2]

Latest posts